



The Board of Directors's adjusted proposal for authorization to resolve on new issues

The Board of Directors of Lumito AB (publ) has decided to adjust its proposal under the item 10 on the agenda for the annual general meeting on 4 June 2019.

The adjustment means that the following passage is removed: " Such new issues may in total be comprised of at most the equivalent of 11,200,000 shares." The reason behind the adjustment is that the authorization shall stay within the boundaries set out in the Articles of Association.

The Board of Directors's adjusted proposal is presented below in its entirety.

The Board of Directors's proposal for resolution on authorization for the Board of Directors to resolve on new issues of shares, warrants and convertibles

The Board of Directors of Lumito AB (publ), reg.no. 556832-0062, ("The Company") proposes that the annual general meeting resolves to authorize the Board of Directors, on one or multiple occasions and in accordance with the stipulations in the Company's Articles of Association, to resolve on new issue of shares, warrants and/or convertibles in order to increase the Company's share capital. The Board of Directors shall be able to resolve on new issue of shares, warrants and/or convertibles with deviation from the share holders' preferential rights, and/or with payment by set-off, payment-in-kind, or otherwise with particular terms and conditions in accordance with the Swedish Companies Act 2 ch. 5 s. second paragraph 1-3 and 5.

An issue in accordance with this authorization shall be on market conditions, subject to a market-based issue discount when applicable. The Board of Directors shall be authorized to decide on the terms and conditions regarding issues under this authorization, and on what persons shall be entitled to subscribe for the shares, warrants and/or convertibles. The reason for the proposal that the Board of Directors shall be authorized to resolve on an issue with deviation from the shareholders' preferential rights and to resolve on an issue in kind or an issue by way of set-off or otherwise on such terms and conditions as referred to above, is that the Company shall be able to issue shares, warrants and/or convertibles in connection with acquisitions of companies or businesses, and to conduct directed issues in order to raise capital for the Company.

The CEO is proposed to be authorized to make such minor adjustments of the terms set out above that are required in order to register the resolution with the Swedish Companies Registration Office.

A resolution according to the Board of Directors's proposal requires for its validity that a minimum of two-thirds of the votes cast and the shares represented support the resolution.

For more information contact:

Lumito AB (publ), CEO Stefan Nilsson, telefon +46 767 78 59 05, sn@lumito.se

Lumito in brief

Lumito is specialised in research and development of imaging technologies for medical applications. The technology is based on so called UCNP:s (Up Converting Nano Particles) and is aiming to increase image quality in biomedical applications. Lumito's IPR covers imaging with high quality of for instance tissue samples, with UCNP:s as markers. The technology has several possible application areas, but Lumito has initially decided to focus on digital pathology. Lumito has an agreement with TTP plc (The Technology Partnership) in Cambridge, UK, regarding development of instruments and staining reagents. Lumito's share Lumito and warrant Lumito TO1 are traded at the NGM Nordic MTF marketplace.